⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTOR News
Citius Oncology, Inc. Common Stock
Form 8-K
sec.gov
CTOR
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
prnewswire.com
CTXR
CTOR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
prnewswire.com
CTXR
CTOR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
prnewswire.com
CTXR
CTOR
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
prnewswire.com
CTXR
CTOR
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
prnewswire.com
ONCY
BCTX
GLSI
CTOR
KZIA
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
prnewswire.com
CTOR
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR